DOMANE- Prepare for Medical Freedom

Air Force contract No. FA8702-15-D-0001

Nothing says “Medical Freedom” quite like untraceable multibillion dollar Air Force Contracts.

I love the smell of DOMANE in the morning. It smells like - Remdesivir.

there aint no Remdesivir down in the tree line can you guys put it down there

right one three we was made to fuck with it what’s the target

suppress the fake virus off the tree lines down there

Air Force contract No. FA8702-15-D-0001 was referenced by Robert Malone in his role with DOMANE, along with MCDC-2015-003 and MCDC-2013-001.

Malone was paid for all sorts of mysterious COVID-related things. Consultant to MIT Lincoln Laboratories. Subcontractor to Leidos. Subcontractor to Quantum Leap Heathcare Collaborative. Unspecified contracts or “consortium agreements” (?) with Defense Threat Reduction Agency (DTRA), Joint Science and Technology Office (JSTO) of the Chemical and Biological Defense Program (CBDP) under DOMANE.

(Note: maybe this is where they hid DOMANE?)

Consultant work for the Air Force, if I read this right? Consultant for Leidos and QLHC under the MCDC contracts. “Personal fees and other” from MIT Lincoln Laboratories.” “COVID-related compensation” from Leidos. Personal fees from Quantum Leap Healthcare Collaborative. Personal fees from Alchem. Personal fees from Evergreen Therapeutics. Personal fees from Chrysalis Biotherapeutics. Personal fees from Reliance Vaccines. Personal fees from Puma Biotechnology. Personal fees from Nanobiosym. Personal fees from ID-Tech Molecular Laboratories.

According to Darnell Gardner of DTRA:

To complement the modest therapeutic effect of Remdesivir, DOMANE also identified Famotidine, a COVID-19 disease modifier from Johnson & Johnson; Pfizer’s Celecoxib, an anti-inflammatory product; and Merck’s Mectizan®, Ivermectin, an antiviral for clinical trials. To learn whether a combination of these FDA-approved drugs is more efficacious than current treatments, DTRA partnered with Quantum Leap Healthcare to conduct a clinical trial.

Below is what little I can find about Air Force contract FA8702-15-D-0001.

APRIL 27, 2015.

This looks like the start date of the Air Force contract FA8702-15-D-0001 which was subbed out to MIT.

Department of Defense Contracts April 27, 2015

The Massachusetts Institute of Technology, Cambridge, Massachusetts, has been awarded a $3,061,852,854 indefinite-delivery/indefinite-quantity contract for the operation of the Lincoln Laboratory Federally Funded Research and Development Center. Contractor will apply advanced technology to problems of national security. Research and development activities focus on long-term technology development as well as rapid system prototyping and demonstration. Work will be performed in Lexington, Massachusetts, and is expected to be complete by March 31, 2020. This award is the result of a sole-source acquisition. Fiscal 2015 operations and maintenance funds in the amount of $600,000 are being obligated at the time of award. Air Force Lifecycle Management Center, Hanscom Air Force Base, Massachusetts, is the contracting activity (FA8702-15-D-0001).

JUNE 3, 2016.

The Air Force transitioned $1,573,614,350 in programs from MIT Lincoln Contract # FA8721-05-C-0002 TO MIT Lincoln Contract # FA8702-15-D-0001.

APRIL 25, 2019

In April 2019, MIT Lincoln was awarded a $2 Billion “modification” to the existing Air Force contract FA8702-15-D-0001 for the Lincoln Laboratory Research and Development Center.

Department of Defense Contracts April 25, 2019.

The Massachusetts Institute of Technology Lincoln Laboratory, Lexington, Massachusetts, has been awarded a $2,038,147,146 modification (P00020) to previously awarded contract FA8702-15-D-0001 for the operation of the Lincoln Laboratory Federally Funded Research and Development Center. This modification provides for advanced technology research and development activities that focus on long-term technology development as well as rapid system prototyping and demonstration. (OF WHAT?)  Work will be performed in Lexington, Massachusetts, and is expected to be complete by March 31, 2020.  This modification brings the total cumulative face value of the contract to $9,600,000,000, and no funds are being obligated at the time of award.  Air Force Life Cycle Management Center, Hanscom Air Force Base, Massachusetts, is the contracting activity.

The Department of Defense did not specify what type of “advanced technology research and development” that MIT Lincoln would be involved with. They DoD did use specific language for other contracts that day, such as: “Lockheed Martin, Orlando, Florida, was awarded a $723,550,174 modification (P00011) to domestic and Foreign Military Sales (Lebanon, Netherlands and France) contract W31P4Q-18-C-0130 to procure a variety of HELLFIRE II missile variants.” It makes you wonder why there was so much secrecy in the DoD language of their award to MIT Lincoln.

MARCH 31, 2020

I can’t find the source again where I took this screenshot. In March 2020, MIT Lincoln Laboratory was awarded $10.5 Billion on #FA8702-15-D-0001 (option P00025). Note that the previous two awards stated that this contract was expected to end on March 31, 2020. Instead they got a huge contract on this date.

Department of Defense Contracts March 31, 2021.

The Massachusetts Institute of Technology Lincoln Laboratory, Lexington, Massachusetts, has been awarded a $10,540,117,466 option (P00025) to contract FA8702-15-D-0001 for the operation of the Lincoln Laboratory Federally Funded Research and Development Center. This option provides for advanced technology research and development activities that focus on long-term technology development, as well as rapid system prototyping and demonstration. Work will be performed in Lexington, Massachusetts, and is expected to be completed by March 31, 2025. This option brings the total cumulative face value of the contract to $20,140,117,466, and no funds are being obligated at the time of award. The Air Force Life Cycle Management Center, Hanscom Air Force Base, Massachusetts, is the contracting activity.

I will note some circumstances of this huge March 2020 contract extension. Robert Malone said he was called by Michael Callahan from somewhere in China on January 4, 2020, and asked to use the DOMANE program with “his team” at Alchem. The next day, January 5, China uploaded the “Wuhan Seafood Market Virus” to GenBank. Malone later told Joe Rogan that in February of 2020 he had acquired a case of COVID that was so severe, that he thought he would die. Malone, however, reported to Rogan that he quickly cured cured himself in February 2020 with Famotidine (which was identified by the DOMANE system). This demostrated just how fast, powerful and useful DOMANE was when faced with fake lab leaks coming out of China.

Then in March, MIT Lincoln Laboratory got a new $10 Billion contract extension on the date the contract was scheduled to end.

If anyone has any suggestions on how to obtain details on the DOMANE program through Freedom of Information requests, please leave those in the comment section. I am looking for details on every person, every company, who was paid under the DOMANE program, not just Robert Malone.

I think we all can agree that a program hidden in secrecy which was so important to the response of the US government, and responsible in a fundamental way to creating the illusion of a viral Pandemic by killing the Chinese with Remdesivir and ventilators and calling it “COVID,’ should be brought into the light. DOMANE is the polar opposite of “Medical Freedom.” It must be exposed and shut down for the sake of the free world.

Robert Malone told Bright Light News on October 2022 that “…there is an unmet need for development of capabilities that will allow rapid responses to engineered and emerging pathogens.” (5:40 mark). The Deparment of Defense controls both the supply and demand for their death and countermeasure program.

In Robert Malone’s defense, I will publish the defense he wrote himself. I could go point by point with this defense and dispute much of it, especially on the suppression of Ivermectin, but my purpose here is not to debate his version of events. I and others want to get information on DOMANE from the United States Government itself.

If Dr. Malone is sincere in his plea of innocence, he will help us understand all of the details of this program instead of hiding behind “various non-disclosure agreements.” We’re not talking about your average government kickback scam here. We’re talking about mass murder.

The block quote section below was written by Robert Malone, June 2, 2023.

To kick this off, there is a fake/fabricated storyline circulating that the US DoD/DTRA- Chem-Bio defense (DOMANE) program actively suppressed the use of Ivermectin as a COVID-19 treatment option, that I was the leader of the DOMANE program, and that I am personally responsible for the advancement and licensure of Remdesivir and the suppression of Ivermectin as a treatment option. The same self-styled “independent journalist” promoting these obvious falsehoods also asserts that I am responsible for 9-11 and the Anthrax attacks.

The following paragraphs are the first time I have directly addressed aspects of my involvement in drug repurposing for COVID involving Ivermectin.

Historically I primarily have spoken out about the COVID genetic vaccines, because that is what people (and podcasters) wanted to hear from me. But that work is only a small subset of my efforts to provide ways to mitigate the damages caused by SARS-CoV-2, COVID-19 and the COVIDcrisis response since January of 2020. My work in repurposing drugs for early COVID-19 treatment, which consumed all of 2020 and most of 2021, is not something that I have emphasized in my public activities for three general reasons: First, others have spoken at length about their work, so the topic of drug repurposing has been fairly well covered. Second, much of my work was performed as a consultant/subcontractor under various non-disclosure agreements. Nothing nefarious here, just normal business practices for a small consulting shop. Third, despite what some may darkly mutter, my public activities have not been about self-promotion, but rather have been focused on trying to educate and help the general public deal with the upside down clown world of the COVIDcrisis public response that they have been subjected to since January 2020.

I have a general rule of thumb to not talk to the crazies, online or otherwise, and so have not previously felt any particular need to address these various unfounded conspiracy theories promoted by a self-styled “independent journalist” who mostly seems to be obsessed with trying to belittle, gaslight, and denigrate me without bothering to actually do the investigative research which would immediately refute his theories. I have no idea who pays this person to spread his theories and attacks on me and many others.

For the record,

• DOMANE is a DoD/DTRA program. I have never been a DTRA employee. I have never been a member of DTRA (or DOMANE) leadership. All lies. In my role as CEO of my consulting business RWMaloneMD LLC I served as a subcontractor for three DTRA-related contracts. One contract was issued to a small company called Allchem, which at the time was owned by Dr. Jim Talton. That contract was focused on discovering inhibitors of organophosphate toxins (nerve gases and certain pesticides) using high throughput computational and robotic screening methods. The other contract was with MIT Lincoln Lab, where I served as a consultant on that DOMANE contract, which was focused on discovering repurposed drugs for treatment of COVID-19 (including Ivermectin) and advancing sponsored clinical research to test those agents. The third one (also acting as a consultant/subcontractor) was managed by Leidos, and involved development of an advanced patient-centered outcomes research software tool and use in supporting both outpatient (virtual) clinical trials as well as parallel inpatient trials of the repurposed pharmaceutical agents ivermectin, celecoxib, and famotidine. No Remdesivir. Amazingly, the FDA blocked that program (and the DoD) from testing Ivermectin, informing that clinical trials of that agent would not be allowed to proceed until in vitro (in the test tube) studies demonstrated the mechanism of action of Ivermectin as an anti-viral for SARS-CoV-2.

• DOMANE is not the program which advanced and advocated Remdesivir for COVID-19. Another obvious lie. That would be Dr. Anthony Fauci and the NIAID. The historic record is clear on that. DOMANE leadership claims credit for funding the initial development of Remdesivir because it funded the development of this drug as a potential anti-Ebola agent, for which application it failed largely due to toxicity and lack of effectiveness.

• I was an early and continued advocate for use of Ivermectin for treatment of COVID-19. Some, although not this particular “investigative journalist” in question, will remember that I was specifically attacked by “independent journalist” Mr. Alex Berenson for my advocacy of the repurposed agent as a treatment for COVID-19. Reviewing my over 3,400 email correspondences involving Ivermectin since January 01, 2020 (there were many more before that date), I find that the first in this time frame is dated January 10, 2020, and involved internal correspondence with the Alchem team (who were volunteering their time to try to identify repurposed drugs for SARS-CoV-2 treatment).

• Most are also not aware that further back in time I had been an advocate for the use of Ivermectin as an agent for treating Yellow Fever Virus infection and many other viruses, and even filed a field of use patent (since abandoned) for Ivermectin as an antiviral.

• Searching my email accounts for the key words “Ivermectin” and “Kory” (as in Pierre) reveals 936 email correspondences, the first being on 11/19/2020 (almost 200 days prior to the Bret Weinstein/Pierre Kory DarkHorse Podcast. This first notification of the potential efficacy of Ivermectin was part of a summary provided by senior (since retired) DTRA/DOMANE scientist Dr. Howard Haimes.

• On December 08, 2020, I wrote to the project officer for the DTRA/DOMANE contractor Leidos concerning the following article posted on Trial Site News, and advocating for clinical testing of Ivermectin within the funded program:

Prominent Physician/Researchers To Present Case For Ivermectin To U.S. Senate Committee On Homeland Security & Governmental Affairs

The U.S. Senate Committee on Homeland Security & Governmental Affairs will hold a full committee hearing on December 8, 2020, at 10:00 AM at the Senate Dirksen Building and via video conference.

Titled “Early Outpatient Treatment: An Essential Part of a COVID-19 Solution, Part II,” invited witnesses to include Jane M. Orient, MD, Executive Director Association of American Physicians and Surgeons, Pierre Kory, MD, Associate Professor of Medicine, St. Luke’s Aurora Medical Center, Jean-Jacques Rajter, MD, Pulmonologist, Broward Health Medical Center and ICON study co-author and Ramin Oskoui, MD, Vice President of Medical Staff, Sibley Memorial Hospital and Chief Executive Officer of Foxhall Cardiology.

Prominent among discussion topics will be the use of ivermectin as a treatment for early-stage, mild to moderate COVID-19 cases. To date, although well over $12 billion U.S. dollars have been spent by the taxpayers, there has been no breakthrough for early-stage treatment, an incredibly important period to get COVID-19 under control.

There is evidence that some generic-based treatments can help accomplish this objective.

In the same email, I further advocated for clinical trial testing of Ivermectin by including a link to this website:

COVID-19 treatment studies for Ivermectin

On December 05, 2020, I reached out to Pierre’s co-author on an informal review of Ivermectin as a COVID-19 treatment (which had been published informally on the internet), which lead to my being introduced to Pierre, launching what I hope will be a lifelong friendship.

Dear Dr Lieberman,

Alexis – Please consider preparing and submitting a report summarizing experiences treating COVID-19 with Ivermectin! We have set up this special topic of Frontiers in Immunology specifically so that there will be a forum for physicians and scientists such as yourself to report observations that may not yet meet the criteria for publication in high profile journals, but which are not otherwise being reported and published.

This journal is “open source”, and so does charge for managing and formatting each publication. Best wishes Robert Malone, MD, MS

Frontiers in Pharmacology has launched a new Research Topic, Treating COVID-19 With Currently Available Drugs. As a leading expert in your field, we would like you to participate by submitting your research.

Pierre wrote back on December 11, 2020:

Alexis, Robert,

Thank you for making our acquaintance and I so appreciate your mention of the short period to publication because:

We know many many lives are at stake with every day that this manuscript takes through peer review. I cannot stress this enough

I am just now getting offers from other journals also emphasizing speed. I am much more attracted to quality and speed right now than just impact factor etc (this is also a first for me in publishing manuscripts, i.e. journals reaching out to me

Anyway, Robert, I thank you for your interest, it is very encouraging – do you know what kind of time-line to on-line publication we can expect if it passes peer review and/or requires only minor revisions. If anything more gets required, we understand it would take much longer. Anyway, thanks for your interest and please advise – thanks, Pierre

Pierre Kory, MD, MPA

President, Front-Line Covid-19 Critical Care Alliance

Associate Professor of Medicine

Advocate Aurora Critical Care Service

St. Luke’s Aurora Medical Center, Milwaukee, WI

Front Line COVID-19 Critical Care Alliance
Prophylaxis & Treatment Protocols for Covid-19
www.covid19criticalcare.com
www.flccc.net

Thus launched at initiative which unfortunately ended poorly. Pierre submitted his manuscript to Frontiers and I was assigned as editor for the submission. I selected four highly qualified reviewers –

1) a senior pharmaceutical scientist,

2) the most senior FDA clinical reviewer,

3) another senior FDA pharmaceutical scientist from the office of the Chief Scientist, and

4) a front line ICU physician practicing at a major academic medical center in NYC/Brooklyn.

These four put the manuscript through extensive review and revisions. It was accepted for publication. Pierre and the FLCCC paid the required publication fee.

As was the usual practice for Frontiers in Pharmacology, the abstract was published as a pre-print/teaser.

It accrued a record number of views in just a few short days. And then all hell broke loose.

The editor in chief of Frontiers forced the paper to be withdrawn. This set off a cascade which eventually lead to resignation of the editors (including myself) who had created this special edition of Frontiers in Pharmacology specifically to enable publication of COVID-19 repurposed drug research, and closing down of that special volume without publication.

At the time, the Editor in Chief was warned that if he took these actions, he would be responsible for large numbers of avoidable deaths. Time has validated that assertion, along with so many others which were made along the way but attacked at the time.

The resulting mess (and Frontiers’ denials of culpability) were then covered in two articles by a UK publication named “The Scientist”:

Frontiers Removes Controversial Ivermectin Paper Pre-Publication

A Review Article Containing Contested Claims About The Tropical Medicine Drug As A COVID-19 Treatment Was Listed As “Provisionally Accepted” On The Journal’s Website Before Being Removed This Week.

Frontiers Pulls Special COVID-19 Issue After Content Dispute

The Issue’s Guest Editors Resign After Falling Out With The Publisher Over The Management Of Papers, Including A Rejected Manuscript On Ivermectin, That Were Submitted For A Special Issue On Drug Repurposing For COVID-19.

You can find an interview between Pierre Kory and Del Bigtree concerning Pierre’s recollections regarding this sorry affair at the following link: dr.-kory-makes-an-astounding-reveal-on-the-highwire

So, I ask you, dear reader. Based on the evidence above, did I serve as the leader of DOMANE, act to promote Remdesivir and block Ivermectin?

These are lies which are being promoted for some undisclosed ulterior motive by someone who self-identifies as an “investigative journalist” and has posted literally thousands of on-line attacks on my character and integrity.

As are the assertions that I am somehow responsible for 9-11 and the Anthrax attacks (at which time I was actually living in Rockville MD working on developing a Breast Cancer research facility and tissue bank in Windber, PA under a John Murtha porkbarrel project called the Windber Research Institute, while also starting a US-based company called Inovio).

The record clearly shows that I was an early and strong advocate for use of Ivermectin (and celecoxib, and famotidine) as repurposed drug agents for treating COVID-19, and a strong advocate for the work of Dr. Pierre Kory and his colleagues at the FLCCC.

The good news to come out of this horrid chapter in the COVIDcrisis story was that through all of this drama and trauma, and subsequently in so much other travel (not to mention thousands of emails!), meetings and discussions (including both “DEFEAT THE MANDATES” rallies), I have been able to develop what I hope will be a livelong friendship with Dr. Pierre Kory and his close colleague Dr. Paul Marik.

Dr. Pierre Kory is the kind of guy people love to love. A native New Yorker with a huge heart and a knack for numbers, Kory is equal parts affable and academic, quick to crack a joke or rattle off complex medical statistics from memory.

He’s been on the Covid front lines from the beginning, searching for answers, testifying before the senate, and advocating for both patient and physician rights—a journey he eloquently and assiduously documents in his forthcoming book, The War on Ivermectin (Skyhorse, June 2023).

Kory has been called everything from a fringe doctor to a medical misinformationist—two terms that in today’s upside-down world translate into “someone you definitely want to listen to.” It’s my pleasure to share the first chapter of his book, written with author Jenna McCarthy and featuring a foreword by Del Bigtree.

Kory’s is a powerful, highly-anticipated story filled with facts, humor and truth that will edify and enlighten readers around the world.

This is taken from a long document. Read the rest here substack.com

---

Charles Wright